drugset / Trial / NCT01824225

Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

NCT01824225

Phase 4 Completed 100 enrolled Nihon University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.

Timeline

Start
2013-03
Primary completion
2014-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic Intravitreal